Medicare Enrolled
Dr. Wayneinder Anand, MD
Pulmonary Disease · Burbank, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Anand from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Anand?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Anand
Dr. Wayneinder Anand is a pulmonary disease specialist in Burbank, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Anand performed 3,258 Medicare services across 1,647 unique beneficiaries.
Between the years covered by Open Payments, Dr. Anand received a total of $6,464 from 42 pharmaceutical and/or device companies across 302 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Anand is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 10% volume in CA
$6,464 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,258
Medicare services
Top 10% in CA for pulmonary disease
1,647
Unique beneficiaries
$106
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~171 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
919 | $99 | $260 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
775 | $176 | $450 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
346 | $98 | $190 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
278 | $66 | $147 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
183 | $87 | $181 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
100 | $140 | $393 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
93 | $37 | $70 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
92 | $33 | $130 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
91 | $51 | $100 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
83 | $23 | $59 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
81 | $104 | $260 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
42 | $97 | $217 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
32 | $10 | $69 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $132 | $275 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
29 | $65 | $125 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
26 | $27 | $280 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
20 | $67 | $225 |
| Emergent tracheostomy An emergency procedure to create an opening in the windpipe to insert a breathing tube, guided by an endoscope. |
17 | $115 | $400 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
11 | $100 | $335 |
| Ultrasound guidance for blood vessel access Use of ultrasound imaging to help locate and access a blood vessel. This guidance assists healthcare providers in performing procedures such as inserting IV lines or drawing blood. |
11 | $12 | $40 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$6,464
Total received (2018-2024)
Avg $923/year across 7 years
Top 24% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
302
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,436 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$28 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,318
2023
$259
2022
$65
2021
$120
2020
$993
2019
$1,881
2018
$1,828
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$256
AstraZeneca Pharmaceuticals LP
$202
Cook Incorporated
$162
Bayer Healthcare Pharmaceuticals Inc.
$150
Amgen Inc.
$98
Grifols USA, LLC
$78
United Therapeutics Corporation
$52
Merck Sharp & Dohme LLC
$51
Novartis Pharmaceuticals Corporation
$50
ANI Pharmaceuticals, Inc.
$44
Boehringer Ingelheim Pharmaceuticals, Inc.
$42
Lilly USA, LLC
$32
Shionogi Inc
$31
Mylan Specialty L.P.
$27
JAZZ PHARMACEUTICALS INC.
$25
Baxter Healthcare
$19
Top 3 companies account for 47.1% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,350
AstraZeneca Pharmaceuticals LP
$850
Boehringer Ingelheim Pharmaceuticals, Inc.
$577
Grifols USA, LLC
$361
Genentech USA, Inc.
$349
Advanced Respiratory, Inc
$330
Novartis Pharmaceuticals Corporation
$267
Philips Electronics North America Corporation
$259
PFIZER INC.
$239
Actelion Pharmaceuticals US, Inc.
$163
Cook Incorporated
$162
Bayer Healthcare Pharmaceuticals Inc.
$150
ADVANCED RESPIRATORY, INC
$122
Regeneron Healthcare Solutions, Inc.
$112
Sunovion Pharmaceuticals Inc.
$100
Amgen Inc.
$98
GENZYME CORPORATION
$97
Allergan Inc.
$81
Merck Sharp & Dohme Corporation
$71
E.R. Squibb & Sons, L.L.C.
$66
Maquet Cardiovascular U.S. Sales, L.L.C.
$65
Gilead Sciences, Inc.
$55
United Therapeutics Corporation
$52
Merck Sharp & Dohme LLC
$51
Novo Nordisk Inc
$45
ANI Pharmaceuticals, Inc.
$44
Lilly USA, LLC
$32
Shionogi Inc
$31
Janssen Pharmaceuticals, Inc
$29
Mylan Specialty L.P.
$27
JAZZ PHARMACEUTICALS INC.
$25
Kowa Pharmaceuticals America, Inc.
$24
Allergan, Inc.
$23
Boston Scientific Corporation
$22
Otsuka America Pharmaceutical, Inc.
$22
Baxter Healthcare
$19
Bayer HealthCare Pharmaceuticals Inc.
$17
Jazz Pharmaceuticals Inc.
$17
Avanir Pharmaceuticals, Inc.
$16
Insmed, Inc.
$16
Circassia Pharmaceuticals Inc
$15
Paratek Pharmaceuticals, Inc.
$12
Top 3 companies account for 42.9% of all-time payments
Associated products mentioned in payments ›
(7999) SRC Undivided · (8874) inCourage · ANORO · ANORO ELLIPTA · AVYCAZ · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CARDIOHELP · CHANTIX · DUPIXENT · ELIQUIS · Esbriet · FASENRA · Fetroja · GENERAL PAIN MANAGEMENT · Hillrom - Vest System Model 105 Home Care · JARDIANCE · LOKELMA · LONHALA MAGNAIR · Livalo · MELKER · MOUNJARO · NUCALA · NUEDEXTA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PREVNAR - 13 · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · SAMSCA · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The MetaNeb System · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · Utibron · VYNDAQEL · Victoza · XARELTO · XOLAIR · XYWAV · Xolair · Xyrem · YUPELRI · ZERBAXA · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
241
Per 100K population
2.4
County median income
$87,760
Nearest hospital
PROVIDENCE SAINT JOSEPH MEDICAL CTR
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Anand is a clinical cardiology specialist, with above-average Medicare volume (top 10% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Anand experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Anand performed 919 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Anand receive payments from pharmaceutical companies?
Yes. Dr. Anand received a total of $6,464 from 42 companies across 302 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Anand's costs compare to other pulmonary diseases in Burbank?
Dr. Anand's average Medicare payment per service is $106. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Anand) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Burbank
Browse pulmonary diseases in Burbank ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology